Curcumin as an adjunct in cancer therapy: systematic review of clinical trials
Mansouri K, Rasoulpoor S, Daneshkhah A, Abolfathi S, Salari N, Mohammadi M, Rasoulpoor S, Shabani S
Published in BMC Cancer
Methodology
Systematic review of clinical trials examining curcumin as an adjunct to chemotherapy across tumour types, including response and toxicity endpoints.
Key Findings
Curcumin adjuncts were associated with improved treatment tolerance and some improvement in response markers, but trials were small and heterogeneous.
Conclusions
Curcumin shows adjunctive promise without established effect on tumour response rate.
Limitations
Small heterogeneous trials; bioavailability varies widely.
Supplements Studied
Curcumin adjuncts were associated with improved treatment tolerance and some improvement in response markers
Outcomes Measured
Curcumin adjuncts were associated with improved treatment tolerance and some improvement in response markers, but trials were small and heterogeneous
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.